Strides Pharma Science Limited Stock Price Today (NSE: STAR)
Fundamental Score
Strides Pharma Science Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Strides Pharma Science Limited share price today is ₹1183.90, up +2.89% on NSE/BSE as of 16 September 2026. Strides Pharma Science Limited (STAR) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹10.91K (Cr). The 52-week high for STAR share price is ₹1231.00 and the 52-week low is ₹768.65. At a P/E ratio of 17.79x, STAR is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 19.66% and a debt-to-equity ratio of 0.54.
Strides Pharma Science Limited Share Price Chart — NSE/BSE Historical Performance
Strides Pharma Science Limited share price chart: 19.69% return over the past month. 52-week high ₹1231.00, 52-week low ₹768.65.
Strides Pharma Science Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1153.40 | ₹1192.00 | ₹1102.00 | ₹1183.90 | 3.98L (Cr) | |
| ₹1183.00 | ₹1203.00 | ₹1127.00 | ₹1150.60 | 4.21L (Cr) | |
| ₹1199.90 | ₹1215.90 | ₹1179.00 | ₹1183.40 | 1.62L (Cr) | |
| ₹1189.00 | ₹1223.00 | ₹1159.70 | ₹1217.00 | 3.04L (Cr) | |
| ₹1187.40 | ₹1217.00 | ₹1181.30 | ₹1195.70 | 3.76L (Cr) | |
| ₹1169.00 | ₹1206.90 | ₹1155.30 | ₹1187.40 | 4.92L (Cr) | |
| ₹1058.70 | ₹1187.60 | ₹1045.00 | ₹1178.80 | 26.17L (Cr) | |
| ₹1053.10 | ₹1066.50 | ₹1040.00 | ₹1059.60 | 2.17L (Cr) | |
| ₹1053.90 | ₹1073.00 | ₹1043.10 | ₹1053.60 | 1.89L (Cr) | |
| ₹1009.40 | ₹1050.10 | ₹1009.40 | ₹1047.80 | 3.27L (Cr) |
Strides Pharma Science Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1025.00 | ₹1223.00 | ₹1009.40 | ₹1183.90 | +15.50% | |
| ₹1034.00 | ₹1056.00 | ₹931.30 | ₹1025.00 | -0.87% | |
| ₹1106.60 | ₹1138.00 | ₹1007.50 | ₹1025.00 | -7.37% | |
| ₹1111.80 | ₹1149.80 | ₹965.50 | ₹1092.90 | -1.70% | |
| ₹1053.30 | ₹1231.00 | ₹1017.10 | ₹1111.80 | +5.55% | |
| ₹956.00 | ₹1107.00 | ₹925.00 | ₹1036.80 | +8.45% | |
| ₹820.10 | ₹952.85 | ₹817.25 | ₹937.75 | +14.35% | |
| ₹855.00 | ₹912.00 | ₹812.00 | ₹851.55 | -0.40% | |
| ₹906.35 | ₹1010.30 | ₹768.65 | ₹877.00 | -3.24% | |
| ₹886.95 | ₹973.90 | ₹836.75 | ₹900.35 | +1.51% | |
| ₹934.40 | ₹1025.00 | ₹870.60 | ₹878.40 | -5.99% | |
| ₹820.00 | ₹978.40 | ₹792.00 | ₹934.70 | +13.99% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Strides Pharma Science Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Strides Pharma Science Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of STAR across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Return on Equity (19.66%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (22.61%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 17.79 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (57.53%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Excellent EPS Growth (15.03% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (15.68% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Strong Cash Generation (₹852.65 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Strong Institutional Confidence (FII+DII: 43.12%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Risk Factors
2 factors identified
Low Promoter Commitment (27.86%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
High Share Pledging Risk (27.27%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
Strides Pharma Science Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Strides Pharma Science Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
38.2/100 | ₹1183.90₹1184 | ₹10912.36₹10912.36 | 17.79Average 17.8 Average | 19.66%Good 19.66% Good | 22.61%Excellent 22.61% Excellent | 0.54Good 0.5 Good | 15.68%Excellent 15.68% Excellent | 7.94%Good 7.94% Good | 0.38% | |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1851.00₹1851 | ₹444110.43₹444110.43 | 36.73Average 36.7 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9395.00₹9395 | ₹248967.50₹248967.50 | 85.25Average 85.2 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4946.00₹4946 | ₹167402.32₹167402.32 | 79.01Average 79.0 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1116.90₹1117 | ₹111466.62₹111466.62 | 24.89Average 24.9 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1373.50₹1374 | ₹110958.20₹110958.20 | 32.91Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1947.50₹1948 | ₹105213.69₹105213.69 | 96.13Average 96.1 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1667.20₹1667 | ₹95930.69₹95930.69 | 26.05Average 26.1 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1143.90₹1144 | ₹95515.65₹95515.65 | 29.57Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2082.70₹2083 | ₹95231.46₹95231.46 | 17.21Average 17.2 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2253.70₹2254 | ₹93077.81₹93077.81 | 45.54Average 45.5 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price444110.43 Cr
- Divi's Laboratories Limited share price248967.50 Cr
- Torrent Pharmaceuticals Limited share price167402.32 Cr
- Zydus Lifesciences Limited share price111466.62 Cr
- Cipla Limited share price110958.20 Cr
Strides Pharma Science Limited PE Ratio History
Historical price-to-earnings ratio for STAR — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹390.50 | ₹900.35 | 2.3x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Strides Pharma Science Limited Dividend History
Annual cash dividends paid by STAR — dividend yield 0.38%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹22.99 Cr |
| FY 2024 | ₹13.52 Cr |
| FY 2022 | ₹22.43 Cr |
| FY 2021 | ₹17.91 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Strides Pharma Science Limited Quarterly Performance
Latest quarterly metrics for STAR — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
13.01%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
57.53%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
7.94%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
15.68%
Compounded annual net profit growth over 5 years
Strides Pharma Science Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for STAR — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Strides Pharma Science Limited Financial Statements
Annual income statement, balance sheet and cash flow for Strides Pharma Science Limited (STAR) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Strides Pharma Science Limited
About STAR (Strides Pharma Science Limited)
Strides Pharma Science Ltd is a global pharmaceutical entity carving a niche through its broad spectrum of development, manufacturing, and commercialization of diverse pharmaceutic...al products. It operates across a wide geographical footprint, strategically positioning itself in key markets across Africa, Australia, North America, Europe, and Asia. The company excels in producing a comprehensive range of finished dosage forms, catering to various therapeutic needs through an array of product formats. This includes everything from conventional tablets and capsules, both hard and soft gelatin, to more specialized formulations like sachets, liquids, nasal sprays, gels, and topical treatments like ointments and creams. This multifaceted approach allows Strides to effectively meet the demands of diverse patient populations and healthcare providers worldwide. Beyond its generic offerings, Strides Pharma is actively involved in the development and marketing of branded generic products, focusing on therapeutic areas with significant growth potential and unmet medical needs. The company has a particular emphasis on chronic therapies, addressing long-term health conditions that require sustained treatment and management. These strategic therapeutic areas encompass women's health, recognizing the specific healthcare needs of women across different life stages, and the central nervous system, targeting neurological and psychiatric disorders. Furthermore, Strides is committed to developing solutions for cardiovascular ailments, reflecting the increasing prevalence of heart-related diseases globally. This focus on branded generics allows Strides to differentiate itself in the market and provide value-added products for both patients and prescribers. Strides Pharma's strength lies in its ability to integrate research and development, manufacturing excellence, and strategic commercial partnerships to deliver high-quality pharmaceutical products to a global audience. Its vertically integrated structure, encompassing API sourcing, formulation development, and commercialization, enables efficient cost management and robust quality control. The company's commitment to innovation, coupled with its deep understanding of regulatory landscapes across various markets, allows it to navigate the complexities of the pharmaceutical industry effectively. By continuously adapting to evolving market dynamics and investing in future growth opportunities, Strides Pharma Science is positioned to sustain its momentum and expand its reach in the years to come.
Company Details
Key Leadership
STAR Share Price: Frequently Asked Questions
What is the current share price of Strides Pharma Science Limited?
Strides Pharma Science Limited (STAR) trades at ₹1183.90 on NSE and BSE. Market cap ₹10.91K (Cr). Educational data only.
What is the P/E ratio of Strides Pharma Science Limited?
Strides Pharma Science Limited has a P/E of 17.79x vs industry average 34.89x.
What is the Bull Run score for Strides Pharma Science Limited?
Strides Pharma Science Limited has a Bull Run score of 38.2/100 based on 25+ financial parameters.
Does Strides Pharma Science Limited pay dividends?
Strides Pharma Science Limited has a dividend yield of 0.38%. Past dividends don't guarantee future payments.
What is the ROE of Strides Pharma Science Limited?
Strides Pharma Science Limited has ROE of 19.66%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Strides Pharma Science Limited?
Strides Pharma Science Limited has debt-to-equity of 0.54.
Is Strides Pharma Science Limited a good investment?
Bull Run gives Strides Pharma Science Limited a score of 38.2/100. This is not investment advice — consult a SEBI-registered advisor.